JP2016529246A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016529246A5 JP2016529246A5 JP2016532263A JP2016532263A JP2016529246A5 JP 2016529246 A5 JP2016529246 A5 JP 2016529246A5 JP 2016532263 A JP2016532263 A JP 2016532263A JP 2016532263 A JP2016532263 A JP 2016532263A JP 2016529246 A5 JP2016529246 A5 JP 2016529246A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- gene
- therapeutic agent
- alkyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000004432 carbon atom Chemical group C* 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 21
- 239000003814 drug Substances 0.000 claims 20
- 229940124597 therapeutic agent Drugs 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 125000005843 halogen group Chemical group 0.000 claims 12
- -1 Methyl (S)-{4- (3′-cyanobiphenyl-4-yl) -2,3,9-trimethyl-6H-thieno [3,2-f] [1,2,4] tri-azolo [ 4,3-a] [1,4] diazepin-6-yl} acetate Chemical compound 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 239000007962 solid dispersion Substances 0.000 claims 5
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 4
- 101150053046 MYD88 gene Proteins 0.000 claims 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- FGNAJWFZOBYZLR-UHFFFAOYSA-N 3h-[1,2,4]triazolo[4,3-a][1,4]diazepine Chemical compound N1=CC=CN2CN=NC2=C1 FGNAJWFZOBYZLR-UHFFFAOYSA-N 0.000 claims 2
- GNMUEVRJHCWKTO-FQEVSTJZSA-N 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- Chemical compound C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NC1=CC=C(O)C=C1 GNMUEVRJHCWKTO-FQEVSTJZSA-N 0.000 claims 2
- 206010069754 Acquired gene mutation Diseases 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- 108700003785 Baculoviral IAP Repeat-Containing 3 Proteins 0.000 claims 2
- 102100021662 Baculoviral IAP repeat-containing protein 3 Human genes 0.000 claims 2
- 101150104237 Birc3 gene Proteins 0.000 claims 2
- 101150001392 CD79B gene Proteins 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 101100219559 Homo sapiens CARD11 gene Proteins 0.000 claims 2
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 claims 2
- 101150101999 IL6 gene Proteins 0.000 claims 2
- 101150046106 IRAK1 gene Proteins 0.000 claims 2
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 claims 2
- 101150099493 STAT3 gene Proteins 0.000 claims 2
- 101100379220 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) API2 gene Proteins 0.000 claims 2
- 101150095338 TLR6 gene Proteins 0.000 claims 2
- 101150090104 TNFRSF17 gene Proteins 0.000 claims 2
- 101150080074 TP53 gene Proteins 0.000 claims 2
- 108010047933 Tumor Necrosis Factor alpha-Induced Protein 3 Proteins 0.000 claims 2
- 102100024596 Tumor necrosis factor alpha-induced protein 3 Human genes 0.000 claims 2
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 150000004683 dihydrates Chemical class 0.000 claims 2
- 230000009477 glass transition Effects 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- 108700025694 p53 Genes Proteins 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 230000037439 somatic mutation Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361862752P | 2013-08-06 | 2013-08-06 | |
| US201361862772P | 2013-08-06 | 2013-08-06 | |
| US61/862,752 | 2013-08-06 | ||
| US61/862,772 | 2013-08-06 | ||
| US201361909703P | 2013-11-27 | 2013-11-27 | |
| US61/909,703 | 2013-11-27 | ||
| PCT/EP2014/002164 WO2015018521A1 (en) | 2013-08-06 | 2014-08-06 | Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016529246A JP2016529246A (ja) | 2016-09-23 |
| JP2016529246A5 true JP2016529246A5 (enExample) | 2017-09-21 |
Family
ID=51298706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016532263A Ceased JP2016529246A (ja) | 2013-08-06 | 2014-08-06 | Ｂｅｔブロモドメイン阻害剤を用いるびまん性大細胞型ｂ細胞性リンパ腫（ｄｌｂｃｌ）の治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20160158246A1 (enExample) |
| EP (1) | EP3030242A1 (enExample) |
| JP (1) | JP2016529246A (enExample) |
| KR (1) | KR20160037201A (enExample) |
| CN (1) | CN105899212A (enExample) |
| WO (1) | WO2015018521A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2902030B1 (en) | 2010-05-14 | 2016-09-14 | Dana-Farber Cancer Institute, Inc. | Thienotriazolodiazepine compounds for treating neoplasia |
| WO2011143660A2 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia |
| EP3066101B1 (en) | 2013-11-08 | 2020-07-29 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
| CN106456653A (zh) | 2014-02-28 | 2017-02-22 | 腾沙治疗公司 | 高胰岛素血症相关病症的治疗 |
| US9968620B2 (en) * | 2014-08-19 | 2018-05-15 | Oncoethix Gmbh | Methods of treating lymphoma using thienotriazolodiazepine compounds |
| SG11201703414VA (en) | 2014-10-27 | 2017-05-30 | Tensha Therapeutics Inc | Bromodomain inhibitors |
| US10702517B2 (en) | 2015-04-22 | 2020-07-07 | Celgene Quanticel Research, Inc. | Bromodomain inhibitor |
| US10683305B2 (en) | 2015-04-27 | 2020-06-16 | Concert Pharmaceuticals, Inc. | Deuterated OTX-015 |
| PE20181068A1 (es) * | 2015-10-02 | 2018-07-04 | Dana Farber Cancer Inst Inc | Terapia de combinacion de inhibidores de bromodominios y bloqueo de puntos de control |
| EP3490553B1 (en) | 2016-07-29 | 2024-08-28 | Oncternal Therapeutics, Inc. | Combination comprising an indolinone compound and its use in the treatment of lymphoma |
| AU2017345468B2 (en) * | 2016-10-20 | 2022-06-02 | Celgene Quanticel Research, Inc. | Bromodomain inhibitor |
| BR112019027473A2 (pt) * | 2017-07-04 | 2020-07-07 | Jiangsu Hengrui Medicine Co., Ltd. | composição farmacêutica e método para preparar a mesma |
| CN107759607B (zh) * | 2017-11-29 | 2019-08-23 | 上海万巷制药有限公司 | 具有抗肿瘤活性的三氮唑并二氮卓化合物及其制备方法 |
| CN107879989B (zh) * | 2017-11-29 | 2020-01-03 | 重庆市中药研究院 | 具有生物活性的3,4,5-取代苯并二氮卓2-酮类药物分子及其制备方法 |
| CN112533620B (zh) * | 2018-03-05 | 2025-03-28 | 慕尼黑工业大学临床教学中心 | 通过溶瘤腺病毒和cdk4/6抑制剂的组合治疗肿瘤 |
| US20230129013A1 (en) * | 2019-12-11 | 2023-04-27 | Tsinghua University | Long non-coding rna letn serving as tumor marker and therapeutic target point |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001095912A1 (fr) * | 2000-06-16 | 2001-12-20 | Mitsubishi Pharma Corporation | Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph |
| KR101600634B1 (ko) * | 2007-12-28 | 2016-03-07 | 미쓰비시 타나베 파마 코퍼레이션 | 항암제 |
| JP5715241B2 (ja) * | 2010-05-14 | 2015-05-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法 |
| EP2902030B1 (en) * | 2010-05-14 | 2016-09-14 | Dana-Farber Cancer Institute, Inc. | Thienotriazolodiazepine compounds for treating neoplasia |
| US9249161B2 (en) * | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| AR084070A1 (es) * | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| MX2014015986A (es) * | 2012-06-25 | 2016-02-11 | Oncoethix Gmbh | Metodo para tratar linfoma utilizando compuestos de tienotriazolodiazepina. |
| EP2900221B1 (en) * | 2012-09-28 | 2019-03-06 | Oncoethix GmbH | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
-
2014
- 2014-08-06 EP EP14748126.1A patent/EP3030242A1/en not_active Withdrawn
- 2014-08-06 CN CN201480055171.2A patent/CN105899212A/zh active Pending
- 2014-08-06 JP JP2016532263A patent/JP2016529246A/ja not_active Ceased
- 2014-08-06 KR KR1020167004844A patent/KR20160037201A/ko not_active Withdrawn
- 2014-08-06 US US14/910,344 patent/US20160158246A1/en not_active Abandoned
- 2014-08-06 WO PCT/EP2014/002164 patent/WO2015018521A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016529246A5 (enExample) | ||
| ES2586588T3 (es) | Derivados tricíclicos, procedimiento para su preparación y su uso como inhibidores de quinasa | |
| RU2591191C2 (ru) | Трициклические пирроло производные, способ их получения и их применение в качестве ингибиторов киназы | |
| JP2017517579A5 (enExample) | ||
| JP2017514907A5 (enExample) | ||
| AU2012327210B2 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| RU2016146102A (ru) | Способ лечения резистентной неходжкинской лимфомы, медуллобластомы и/или alk+ немелкоклеточного рака легкого с применением тиенотриазолодиазепиновых соединений | |
| JP2017529332A5 (enExample) | ||
| WO2012139930A1 (en) | Pyrazolyl-pyrimidine derivatives as kinase inhibitors | |
| JP2016538310A5 (enExample) | ||
| JP2014513140A5 (enExample) | ||
| CN104039798A (zh) | 具有蛋白激酶抑制活性的噻吩并[3,2-d]嘧啶衍生物 | |
| JP2017511357A5 (enExample) | ||
| JP2013539789A5 (enExample) | ||
| JP2012136540A5 (enExample) | ||
| PE20151601A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso | |
| RU2015133528A (ru) | Замещенные полициклические пиразольные ингибиторы киназной активности и их применение | |
| JP2015528447A5 (enExample) | ||
| JP2015504091A5 (enExample) | ||
| BRPI0411868B1 (pt) | derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase | |
| JP2017504635A5 (enExample) | ||
| JP2014518544A5 (enExample) | ||
| RU2015117251A (ru) | Новые соединения | |
| JP2012513416A5 (enExample) | ||
| JP2013540712A5 (enExample) |